Table 5.

The post-transplant outcomes between different immunosuppressant regimens

Post-transplant complications	TAC+MMF (N=1,380)	CsA+MMF (N=163)	CsA+TAC+MMF (N=81)	p-value
Bacteremia	83 (6.01%)	11 (6.75%)	16 (19.75%)	<0.0001*
Pneumonia	13 (0.94%)	5 (3.07%)	2 (2.47%)	0.0362*
UTI	53 (3.84%)	8 (4.91%)	9 (11.11%)	0.0069*
Myocardial infarction	12 (0.87%)	0 (0%)	1 (1.23%)	0.4329
Cerebral stroke accident	21 (1.52%)	5 (3.07%)	2 (2.47%)	0.2138
Renal failure	55 (3.99%)	8 (4.91%)	9 (11.11%)	0.0097*
Liver cancer	100 (7.25%)	4 (2.45%)	7 (8.64%)	0.0580
Non-liver malignancy	53 (3.84%)	9 (5.52%)	6 (7.41%)	0.1989
Death	158 (11.45%)	17 (10.43%)	18 (22.22%)	0.0120*

Notes: Post-transplant clinical outcomes were defined as infection, cardiovascular events, de novo malignancies, and death occurring 6 months after liver transplantation. Liver transplant recipients of regimen CsA+TAC+MMF had the worst clinical outcomes among all the regimens with higher incidence of bacteremia (p<0.001), pneumonia (p=0.036), UTI (p=0.007), renal failure (p=0.009), and mortality rate (p=0.012);

^*p<0.05.

Abbreviations: TAC, tacrolimus; MMF, mycophenolate mofetil; CsA, cyclosporine; UTI, urinary tract infection.